Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (8.728.185 €): Beschleunigte Entwicklung und Verbesserung des Zugangs zur CAR- und TCR-entwickelten T-Zelltherapie Hor26.11.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Beschleunigte Entwicklung und Verbesserung des Zugangs zur CAR- und TCR-entwickelten T-Zelltherapie
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| 718.625 € | |
| Astellas Pharma Europe B.V. | 0,00 € |
| BAYER AG | 0,00 € |
| BUNDESINSTITUT für IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | 479.000 € |
| Biosci Consulting BVBA | 476.000 € |
| CELGENE MANAGEMENT Sàrl | 0,00 € |
| Erasmus Universiteit Rotterdam | 78.125 € |
| European Cancer Patient Coalition | 37.621 € |
| 0,00 € | |
| 0,00 € | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 539.750 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 510.689 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Information Technology FOR Translational Medicine (Ittm) SA | 312.500 € |
| 454.000 € | |
| Institut National du Cancer GIP | 551.260 € |
| Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion | 271.310 € |
| Institut de Recherches Internationales Servier Iris | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| MILTENYI BIOTEC B.V. & Co. KG | 277.500 € |
| Medizinische Universitaet Wien | 571.911 € |
| Ospedale Pediatrico Bambino Gesu | 560.600 € |
| PATVOCATES GmbH | 87.600 € |
| Stichting Amsterdam UMC | 0,00 € |
| T-CURX GmbH | 253.750 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 562.750 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 612.774 € |
| Universidad de Navarra | 271.370 € |
| Universita Vita-Salute SAN Raffaele | 629.550 € |
| University College London | 471.500 € |
Quelle: https://cordis.europa.eu/project/id/945393
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam - EU-Förderung (8.728.185 €): Beschleunigte Entwicklung und Verbesserung des Zugangs zur CAR- und TCR-entwickelten T-Zelltherapie"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
